| Missing (N=59) |
PD-L1 TPS (N=43) |
P-value | |
|---|---|---|---|
| Age(years) | |||
| Mean (SD) | 64.5 (7.34) | 63.5 (9.58) | 0.551 |
| Median [Min, Max] | 66.0 [49.0, 78.0] | 63.0 [33.0, 80.0] | |
| Sex | |||
| FeMale | 6 (10.2%) | 5 (11.6%) | 1 |
| Male | 53 (89.8%) | 38 (88.4%) | |
| Smoking | |||
| No | 18 (30.5%) | 14 (32.6%) | 0.997 |
| Yes | 41 (69.5%) | 29 (67.4%) | |
| Pathologic subtype | |||
| Non squamous | 31 (52.5%) | 27 (62.8%) | 0.407 |
| Squamous | 28 (47.5%) | 16 (37.2%) | |
| PFS(months) | |||
| Mean (SD) | 12.2 (5.55) | 15.0 (7.26) | 0.362 |
| Median [Min, Max] | 12.2 [0.367, 26.3] | 14.5 [1.23, 27.9] | |
| OS(months) | |||
| Mean (SD) | 13.3 (5.81) | 16.1 (7.03) | 0.42 |
| Median [Min, Max] | 14.1 [0.367, 26.3] | 16.2 [1.23, 27.9] | |
| Clinical benefit | |||
| DCB | 51 (86.4%) | 38 (88.4%) | 0.691 |
| NDB | 7 (11.9%) | 5 (11.6%) | |
| Unknown | 1 (1.7%) | 0 (0%) | |
| LDH | |||
| Mean (SD) | 271 (234) | 202 (90.6) | 0.302 |
| Median [Min, Max] | 199 [96.0, 1660] | 174 [111, 518] | |
| Missing | 3 (5.1%) | 2 (4.7%) | |
| NLR | |||
| Mean (SD) | 4.40 (2.97) | 3.57 (2.34) | 0.457 |
| Median [Min, Max] | 3.73 [1.17, 16.3] | 2.82 [1.15, 14.0] | |
| Missing | 1 (1.7%) | 1 (2.3%) | |
| Bone metastasis | |||
| No | 29 (49.2%) | 22 (51.2%) | 1 |
| Yes | 30 (50.8%) | 21 (48.8%) | |
| Brain metastasis | |||
| No | 53 (89.8%) | 33 (76.7%) | 0.129 |
| Yes | 6 (10.2%) | 10 (23.3%) | |
| Liver metastasis | |||
| No | 47 (79.7%) | 36 (83.7%) | 0.793 |
| Yes | 12 (20.3%) | 7 (16.3%) | |
| Pleura metastasis | |||
| No | 41 (69.5%) | 30 (69.8%) | 1 |
| Yes | 18 (30.5%) | 13 (30.2%) | |
| Lymph metastasis | |||
| No | 16 (27.1%) | 20 (46.5%) | 0.0697 |
| Yes | 43 (72.9%) | 23 (53.5%) |